Brief · Use case · Innovation
DTx HbA1c Evidence Review.
LiveEvidence ReviewReview the evidence on whether prescription digital therapeutics lower HbA1c in adults with type 2 diabetes, with certainty rated per outcome.
DTx HbA1c Evidence Review is a ready-made use case for Innovation. It ships under the Evidence Review template.
For digital health and medical leads. You get the PICO, the main studies with effect and risk of bias, certainty per outcome with the reason and what the evidence leaves open. Studies are cited or marked as gaps.
Add it to your library to reuse from New → From template. Edit the saved copy in your library on the service form.
The decision
What does the published evidence show on whether prescription digital therapeutics lower HbA1c in adults with type 2 diabetes?
What is reviewed
Several recent reviews have pooled this question, and their estimates differ by what they count. The review starts from them and reads the studies behind them.
| Evidence | What it holds | What the review does with it |
|---|---|---|
| Pooled randomized trials | A 2025 meta-analysis of 19 studies (3,264 participants) across diabetes types reported a weighted mean difference of −0.54 percentage points in HbA1c (95% CI −0.72 to −0.36). It mixes type 1, type 2 and prediabetes.1 | Reported as found; the type 2 estimate is not separated. |
| Multimodal apps in type 2 | A type 2 review of app-based therapies that mostly meet the German DiGA criteria reported a mean within-group HbA1c reduction of −0.79 (95% CI −1.02 to −0.55), with low to very low quality of evidence. Within-group change is not a comparison with a control.2 | Shown beside the between-group estimates and labeled as a different measure. |
| Network meta-analysis | A network meta-analysis of 75 trials and 9,764 participants compared digitally assisted interventions for glycemic control and rated certainty with CINeMA.3 | Its HbA1c estimates must be read from the full paper. |
What the review does
The answer depends on the comparison. Pooled estimates for type 2 diabetes range from roughly 0.3 to 0.8 percentage points depending on whether the figure is a difference against usual care or a change within the treated group. The review keeps the two apart and does not average them.1,2
Certainty is low to moderate. Participants cannot be blinded to software, attrition is common, and adherence is reported inconsistently. The review lowers certainty for risk of bias and indirectness and says which trials drive the result.2
Intensity may matter. A conference analysis found larger reductions for higher-intensity interventions. It is an abstract sponsored by a manufacturer, and the review labels it as such.
What it cannot yet say. Durability beyond 12 months, effect in people with low digital literacy, and comparison with active treatment.
Recommended length
Standard
The question is narrow and the studies are few enough to tabulate. Standard carries the PICO, the studies, the effect, the certainty and the open question in about 1,300 words.
You can pick another length on the form. The other two stay available.
Assumptions the review checks
The review states the assumptions its question and its rating rest on, and says what each gap limits. Examples for this question:
- Trials in mixed populations can be read for type 2 diabetes.
- HbA1c at the main time point is comparable across trials.
- The products reviewed are prescription digital therapeutics and not general wellness apps.
Standards, guidance and sources
Evidence
The decision practice behind the memo itself is on the template page.
What gets flagged
Any estimate that is a within-group change, any pooled figure that mixes diabetes types, and any result from a sponsored abstract.
What arrives
- The question and the bottom line
- How the evidence was found
- The evidence
- What it shows
- How strong it is
- Where studies disagree
- Where the evidence is thin
- What the evidence does not answer
What it will not do
It is a rapid review, not a systematic one. It reports the effects the studies reported, does not pool them into a new estimate, and labels every certainty rating as analyst judgment.
It does not recommend a product.
It is not a systematic review. It uses a bounded search, says so, and recommends a full literature review when completeness matters.
It does not pool studies into a new estimate. It reports the effects the studies reported.
It does not compute a missing interval or plot a missing effect as zero. Both are marked as gaps.
References
- [1] Impact of Digital Therapeutics for the Management of Adult Patients With Diabetes: Systematic Review and Meta-Analysis of Randomized Controlled Trials. 2025. Figures as given in search excerpts; the paper was not read in full.
- [2] Effect of Multimodal App-Based Interventions on Glycemic Control in Patients With Type 2 Diabetes: Systematic Review and Meta-Analysis. 2025. Figures as given in search excerpts; the paper was not read in full.
- [3] Comparative efficacy of digitally assisted interventions for glycemic control in type 2 diabetes: network meta-analysis. Repository record; trial and participant counts as listed there. HbA1c estimates were not retrieved.
Links checked 9 October 2026
These are the sources the template drew on. None of their authors or issuers has reviewed it.
About the Brief service
A Brief is a written answer from one specialist, at the depth you asked for. It arrives with its sources, and it closes by saying plainly what would change the conclusion. Nothing is hidden behind a summary, and anything the expert could not source is marked as a gap rather than filled in.
To edit a saved template, open New → Brief → From template, or the library rail on the service form.